Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue
Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investors welcomed the company’s receipt of $100 million in payments from Sarepta Therapeutics Inc.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 10,600,000 | $167,480,000 | -5% | 2.93% |
| 2. | Slate Path Capital David Greenspan | 5,232,000 | $82,665,600 | 1.43% | |
| 3. | Siren L.L.C. Raymond Debbane | 2,669,880 | $42,184,104 | 2.18% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,155,998 | $34,064,769 | +3508% | 0.04% |
| 5. | Baker Bros. Advisors Julian Baker And Felix Baker | 939,174 | $14,838,949 | 0.14% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | $11,000.00 | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | $12,500.00 | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | $4,101.00 | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | $23,375.00 | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | $11,200.00 | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 9,389 | $187,780.00 | 262,122 | 2025-08-15 | Filing | |
| $20.00 | 611 | $12,220.00 | 271,511 | 2025-08-13 | Filing | |
| $11.49 | 50,800 | $583,692.00 | 3,921,255 | 2025-04-11 | Filing | |
| $10.87 | 50,000 | $543,500.00 | 3,972,055 | 2025-04-10 | Filing | |
| $11.76 | 1,617 | $19,015.92 | 4,022,055 | 2025-04-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,424,887 | $306,913,213 | 0.01% | |
| 2. | 15,525,072 | $245,296,137 | 0% | |
| 3. | 6,371,056 | $100,662,685 | 0% | |
| 4. | 5,170,310 | $81,690,906 | 0% | |
| 5. | 2,978,505 | $47,066,861 | 0% |
News See All
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call.
Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biotechnology company specializing in RNA interference (RNAi) therapeutics for diseases with high unmet medical needs.
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns
Last week, the FDA ordered Sarepta Therapeutics to stop selling Elevidys drugs following the death of two patients while undergoing treatment.
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn't Make Any Money”
We recently published a list of Jim Cramer’s Thoughts on These 12 Stocks. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc.
Jim Cramer’s Thoughts on These 12 Stocks
On Tuesday’s episode of Mad Money, host Jim Cramer expressed concern over how President Donald Trump's actions have been impacting the stock market as he pointed out the confusion they create among ...
Arrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a Study
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has initiated the human trial of ARO-ALK7, a novel RNA interference (RNAi) therapeutic targeting adipose-specific gene expression to combat obesity.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, welcome to the Arrow Pharmaceuticals Conference Call. Throughout today’s recorded presentation, all participants will be in a listen-only mode.
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps.
Billionaire Hedge Funds
